Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders

Chemical & Pharmaceutical Bulletin
Satoshi MikamiTakahiko Taniguchi

Abstract

It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in neuropsychiatric and neurodegenerative disorders through augmentation of cyclic nucleotide signaling pathways in brain regions associated with learning and memory. Following our earlier work, this article describes a drug design strategy for a new series of lead compounds structurally distinct from our clinical candidate 2 (TAK-915), and subsequent medicinal chemistry efforts to optimize potency, selectivity over other PDE families, and other preclinical properties including in vitro phototoxicity and in vivo rat plasma clearance. These efforts resulted in the discovery of N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20), which robustly increased 3',5'-cyclic guanosine monophosphate (cGMP) levels in the rat brain following an oral dose, and moreover, attenuated MK-801-induced episodic memory deficits in a passive avoidance task in rats. These data provide further support to the potential therapeutic utility of PDE2A inhibitors in enhancing cognitive performance.

References

Feb 9, 2002·European Journal of Pharmacology·Jos PrickaertsArjan Blokland
Nov 19, 2003·The Journal of Comparative Neurology·Wilma C G Van StaverenJan De Vente
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Sep 14, 2006·Pharmacological Reviews·Andrew T Bender, Joseph A Beavo
Dec 22, 2006·Journal of Medicinal Chemistry·Stephen A Hitchcock, Lewis D Pennington
Jun 8, 2007·The European Journal of Neuroscience·Elisabet Reyes-IrisarriJan de Vente
Aug 11, 2007·Expert Opinion on Drug Safety·Kevin R Stein, Noah S Scheinfeld
Feb 23, 2008·Schizophrenia Research·Rajiv TandonHenry A Nasrallah
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Jun 3, 2008·Schizophrenia Research·Rajiv TandonHenry A Nasrallah
Mar 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kris RuttenJos Hhj Prickaerts
Jun 10, 2009·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Diane T StephensonDaniel Morton
Aug 25, 2009·Lancet·Jim van Os, Shitij Kapur
Oct 22, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hiroshi SugimotoToshiya Moriwaki
Feb 12, 2011·Behavioural Brain Research·F Josef van der StaayArjan Blokland
Apr 18, 2012·Journal of Medicinal Chemistry·Stephen A Hitchcock
Sep 25, 2012·Neuroscience·D T StephensonF S Menniti
Jan 30, 2013·Neuropharmacology·Thomas M Sanderson, Emanuele Sher
Jun 1, 1950·Chemical Reviews·E WARE
Sep 16, 2014·ACS Medicinal Chemistry Letters·Peter BuijnstersJosé-Ignacio Andrés
Mar 31, 2015·ACS Medicinal Chemistry Letters·Frederik J R RomboutsAndrés A Trabanco
Jun 21, 2016·Expert Opinion on Therapeutic Patents·Andrés A TrabancoFrederik J R Rombouts
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor

❮ Previous
Next ❯

Citations

Jun 30, 2019·The Journal of Pharmacology and Experimental Therapeutics·Guibao GuAnne Danks
Mar 21, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Zahraa HaidarEliane Chouery
Aug 8, 2019·Nature Reviews. Drug Discovery·George S BaillieMichy P Kelly
May 2, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Badr JismyMohamed Abarbri
Sep 20, 2019·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Seyed Mohammad NabaviMohammad Hosein Farzaei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.